Oncology


Novel Treatment Advances and Approaches in the Management of Hepatocellular Carcinoma (HCC): Expert Strategies for Improved Patient Outcomes

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. Liver cancer is still on the rise and death rates are increasing faster than any other type of cancer. Prognosis is especially poor for those with unresectable HCC. Fortunately for patients with HCC, new agents have recently been approved that provide new options for clinicians in the first-line setting. For the treatment of HCC, transplantation is an option for patients, but there is a limited supply of good-quality donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible, in unresectable HCC. Fortunately, new options are on the cusp of becoming available in the first-line setting for the first time in 10 years. These options include targeted therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs). In addition to newly approved therapies, combination therapy in the second line setting is also changing the treatment paradigm.
Physician, Nursing and CMCN credits valid to August 1, 2020

New Horizons in the Treatment and Management of B-Cell Non-Hodgkin Lymphoma: A Closer Look at the Role of Emerging Therapies

Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. B-cell lymphomas make up most (about 85%) of the NHL in the United States, with diffuse large B-cell lymphoma (DLBCL) being the most common at one in three b-cell lymphomas. Recent advances in disease management and our understanding of the biology of NHL have led to a dramatic change in the treatment landscape. Despite this progress, most b-cell NHL has a poor prognosis. Fortunately for patients with NHL, several new agents have become available, including targeted therapy options. They have shown the ability to improve safety and efficacy outcomes, especially in patients with relapsed disease that have had other therapies. However, with each new treatment, medical directors, oncologists, nurses and other healthcare professionals must stay abreast of the underlying mechanisms, current data, and treatment-emergent adverse events to provide their patients with optimal care. The amount of information surrounding emerging treatments for NHL can be daunting; this conference session will provide these healthcare professionals with a much-needed, concise overview of the available data and treatment paradigm.

There are various treatment options for NHL based on the severity of associated symptoms and the rate of cancer growth. Active treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing based on testing during follow-up visits. After treatment, many patients can go into a remission that lasts for years; however, this disease should be considered a lifelong condition. Thus relapsed (returns after treatment) disease can occur. Fortunately, clinicians have been equipped with new targeted options for many of the b-cell NHLs, including bruton tyrosine kinase (BTK) inhibitors, in the past few years for patient’s whose disease has relapsed, which provide options for the unmet need of treatment in b-cell NHL. Additionally, the BTK inhibitors that have been approved have indications are growing to include more and more types of b-cell NHL. These options have shown improved efficacy and safety in b-cell NHL, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.
Physician, Nursing and CMCN credits valid to August 1, 2020

New Frontiers in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at the Role of Emerging Therapies

Multiple myeloma (MM) is a systemic malignancy of plasma cells that is highly treatable but rarely curable. The median survival in the prechemotherapy era was about 7 months however new and emerging treatment options are currently undergoing late stage clinical trials and have shown great outcomes and real-world data in their ability to improve clinical and economic outcomes. MM is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, amongst other factors. The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Treatment is directed at reducing the tumor cell burden and reversing any complications of disease, such as renal failure, infection, hyperviscosity, or hypercalcemia with appropriate medical management. MM remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies.
Physician, Nursing and CMCN credits valid to August 1, 2020

Evolving Considerations in the Treatment of Metastatic Bladder Cancer: A Closer Look at the Role of Immunotherapy

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. New and emerging treatments, in particular, immune checkpoint inhibitors such as programmed death-1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) inhibitors have changed the treatment paradigm. Checkpoint inhibitors have shown activity in patients with metastatic bladder cancer in both the second line setting and the first-line settings. Some of the new immunotherapeutic options target a protein known as PD-L1 that is expressed at high levels on some cancer cells, while others target PD-1, the receptor protein for PD-L1, on immune cells. Normally, binding of PD-L1 to PD-1 tamps down immune activity. By preventing the interaction between PD-L1 and PD-1, all of these new options can allow the immune system to be more active against tumor cells.
Physician, Nursing and CMCN credits valid to August 1, 2020

Individualizing Treatment in the Management of Advanced Breast Cancer: How Novel Therapies Are Changing the Treatment Paradigm

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. The incidence in women in the United States is 1 in 8 (about 12 percent). Death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options, however therapy in the metastatic setting focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents have recently become available. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HER2- metastatic breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Thankfully, therapy for advanced breast cancer is increasingly personalized due to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents, including PARP inhibitors, have been recently introduced and are changing the treatment paradigm.
Physician, Nursing and CMCN credits valid to August 1, 2020

Improving Clinical and Economic Outcomes with Personalized Treatment in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the second most common cancer in both men and women, accounting for about 15% of all new cancers and it is expected that there will be about 222,500 new cases of lung cancer in 2019. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. More people die of lung cancer than of colon, breast, and prostate cancers combined. NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Fortunately, more comprehensive information has been gathered regarding tumor characterization which have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Additionally, new treatments have just become available for patients with advanced NSCLC that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, giving yet another important option in the evolving management of NSCLC.
Physician, Nursing and CMCN credits valid to August 1, 2020

Novel Treatment Advances and Approaches in Acute Myeloid Leukemia (AML): Expert Strategies for Improved Clinical and Economic Outcomes

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The five-year survival rate has not improved in older patient’s despite 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have begun to drastically change the treatment paradigm. AML has several subtypes and treatment and prognosis vary among subtypes. After AML has been diagnosed, tests are done to find out the subtype. This is especially important, as several new treatments focus on AML disease with certain mutations, including IDH2. Following older treatment paradigms, AML has been cured in 35–40% of people under 60 years old, but only in 5–15% of people over 60 years old.
Physician, Nursing and CMCN credits valid to August 1, 2020

Best Practices in the Management of Metastatic Colorectal Cancer (mCRC): Expert Perspectives on an Evolving Treatment Paradigm

Colorectal cancer is the development of cancer from the colon or rectum. People with colorectal cancers that have not spread to distant sites usually have surgery as the main or first treatment. However, for patients with disease that has spread, or become metastatic, surgery is unlikely to cure the disease, and other treatments must be considered, including chemotherapy and targeted therapies, both alone and in combination. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. However, the prognosis of patients with mCRC has significantly improved in recent years with the introduction of inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Additionally, new treatments have just become available for patients with mCRC that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, giving yet another important option in the evolving management of mCRC.
Physician, Nursing and CMCN credits valid to August 1, 2020

Integrating New and Emerging Targeted Therapies into the Tx Paradigm in Ovarian Cancer: Expert Strategies for Improved Patient Outcomes

For ovarian cancer patients, the five year survival rate is only 45%. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. Fortunately for patients with ovarian cancer, the treatment paradigm has greatly changed, providing more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy.
Physician, Nursing and CMCN credits valid to August 1, 2020

New Treatment Paradigms in CRPC: Enhancing Care through Emerging Diagnostics and Novel Therapies

Prostate cancer remains the second leading cause of cancer deaths among American men. These deaths are typically the result of castration-resistant prostate cancer (CRPC), which occurs when patients’ disease progresses despite castrate levels of testosterone. The treatment of CRPC has dramatically changed over the past decade. For many years, cytotoxic chemotherapy with docetaxel was the common form of treatment for patients with symptomatic or rapidly progressing disease. Since the approval of docetaxel, five additional therapeutic agents showing a survival benefit have been approved by the FDA in clinical trials. These include enzalutamide and abiraterone acetate, two agents designed specifically to affect the androgen axis; sipuleucel-T, which stimulates the immune system; cabazitaxel, a chemotherapeutic agent; alpharadin (or radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent; and the new generation antiandrogen agent enzalutamide.

Another recent success in CRPC is the improvement of understanding biologics and molecular drivers of prostate cancer growth and progression. These advances in the past few years have resulted in the investigations of several novel targeted therapies, including androgen receptor (AR) targeting agents, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. Several of these drugs have either received approval from the FDA or have late stage development based on improvement of intermediate surrogate endpoints such as PSA levels or circulating tumor cell (CTC) counts in recent clinical trials.
Physician, Nursing and CMCN credits valid to August 1, 2020

The Promise of Immunotherapy in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): What Managed Care Needs to Know

Cutaneous squamous-cell carcinoma (CSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for CSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have CSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with CSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.

Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced CSCC.
Physician, Nursing and CMCN credits valid to June 1, 2020

A Deeper Look into Immunotherapies in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Improving Clinical and Economic Outcomes

Cutaneous squamous-cell carcinoma (cSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for cSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have cSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with cSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.
Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced cSCC.
Physician, Nursing and CMCN credits valid to June 1, 2020

Improving Patient Adherence and Quality of Life in Advanced CSCC: Anticipating and Managing Adverse Events

Cutaneous squamous-cell carcinoma (CSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for CSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have CSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with CSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.
Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced CSCC.
Physician, Nursing and CMCN credits valid to June 1, 2020

Comparative Effectiveness and Coordinated Care in Advanced CSCC: What Does Managed Care Need to Know about Immunotherapies?

Cutaneous squamous-cell carcinoma (CSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for CSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have CSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with CSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.
Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced CSCC.
Physician, Nursing and CMCN credits valid to June 1, 2020

The Promise of Immunotherapy in the Management of Gastrointestinal Cancers: What Does Managed Care Need to Know About Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard.
Physician, Nursing and CMCN credits valid to April 1, 2020

Molecular Complexities and Biomarkers in Gastrointestinal Cancers: Addressing Unmet Needs in the Evolving Paradigm of Immunotherapies

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard. What’s the latest from clinical trials assessing immunotherapies in different GI cancers? When and how should MSI/MMR status and PD-L1 expression testing be performed to guide clinical decisions? What does managed care need to know? These and other key topics are explored by top experts in this webinar series.

This webinar is part 1 of a 3-part live webinar series on immunotherapies in GI Cancers. This webinar will focus on molecular complexities and biomarkers in GI cancer and how they help shape treatment.
Physician, Nursing and CMCN credits valid to April 1, 2020

A Deeper Look into Checkpoint Inhibitors in the Management of MSI-High Colorectal Cancer: What Does the Latest Evidence Have to Say?

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard.
Physician, Nursing and CMCN credits valid to April 1, 2020

The Present and Future of Immunotherapy in Gastrointestinal Cancers: What Does
Managed Care Need to Know to Improve Clinical and Economic Outcomes?

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard.
Physician, Nursing and CMCN credits valid to April 1, 2020

Optimal Approaches to the Treatment of Castration-Resistant Prostate Cancer

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients’ disease progresses despite castrate levels of testosterone.

Patients with all stages of CRPC have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer. This marker is used for early diagnosis and monitoring for disease recurrence.

The advances in treatment options in the past few years include the investigations of several novel targeted therapies, including androgen receptor (AR) targeting agents, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. Several of these drugs have either received approval from the FDA or have late stage development based on improvement of intermediate surrogate endpoints such as PSA levels or circulating tumor cell (CTC) counts in recent clinical trials. While the understanding of AR synthesis and regulation is well studied, no predictive markers have been adopted to guide development for the central pathway in early stage prostate cancer.
Physician, Nursing and CMCN credits valid to February 1, 2020

New Horizons in The Management of Acute Myeloid Leukemia (AML): How Novel Therapies Are Changing the Treatment Paradigm

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. AML has several subtypes and treatment and prognosis vary among subtypes. After AML has been diagnosed, tests are done to find out the subtype which is especially important, as several new treatments focus on AML disease with certain mutations, including IDH2. Following older treatment paradigms, AML has been cured in 35–40% of people under 60 years old, but only in 5–15% of people over 60 years old. Fortunately for people with AML, that treatment paradigm has begun to change drastically, as novel targeted agents have shown improved efficacy and safety outcomes in clinical trial research. The emerging predictive and prognostic factors, identification of patients who will benefit from these novel therapies, and recent clinical research on new targeted agents, novel cytotoxic agents, and epigenetic modifiers will ultimately optimize the treatment of patients with AML.
Physician, Nursing and CMCN credits valid to February 1, 2020

Improving Clinical and Economic Outcomes with Emerging Therapies in the Management of Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow and is the most common type of leukemia in adults. CLL affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Furthermore, patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Several new treatments have become available in the last few years, giving clinicians many new options to improve patient outcomes. Additionally, some of these new options have had recent advances which have opened up the number of patients who are eligible to receive these treatments. This presentation focuses on these evolving options, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.
Physician, Nursing and CMCN credits valid to February 1, 2020

New Frontiers in the Management of Ovarian Cancer: Exploring the Role of PARP Inhibitors in the Evolving Treatment Paradigm

Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five-year survival rate is only 45%. Recently, more options in managing patients with ovarian cancer have emerged. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. It is important for healthcare professionals to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.
Physician, Nursing and CMCN credits valid to February 1, 2020

PARP Inhibition and its Evolving Use in the Treatment of Cancers: What Managed Care Needs to Know for Improved Clinical and Economic Outcomes

A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.

This multi-part program will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.
Physician, Nursing and CMCN credits valid to February 1, 2020

Comparative Effectiveness and Coordinated Care in PARP Inhibitors: What Does Managed Care Need to Know?

A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
Physician, Nursing and CMCN credits valid to February 1, 2020

A Deeper Look into PARP Inhibitors in the Management of Ovarian, Breast and Prostate Cancers: Individualizing Treatment for Improved Clinical and Economic Outcomes

A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
Physician, Nursing and CMCN credits valid to February 1, 2020

Improving Patient Adherence and Quality of Life in Managing Cancers with PARP Inhibitors: Strategies for Anticipating, Recognizing, and Managing Adverse Events

A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
Physician, Nursing and CMCN credits valid to February 1, 2020

Optimizing Treatment Strategies in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualized Therapy for Improved Patient Outcomes

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 155,870 deaths from lung cancer in 2018, accounting for around 29% of all cancer deaths. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around EGFR mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer.

Molecular testing has now become a critical part of selecting treatment for patients with advanced NSCLC. Nearly two-thirds of NSCLC patients who are EGFR mutation-positive and experience disease progression after being treated with an EGFR-TKI develop a T790M resistance mutation, for which there have been limited treatment options. However, new indications and agents are now becoming available for patients with EGFR-TKI that has a T790M resistance mutation. Additionally, the first-line management of advanced EGFR-mutated advanced NSCLC has begun to change with new indications bringing more options to the table. As non-small cell lung cancer therapies and treatments continue to both grow and change, it is imperative that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options that can greatly improve a patient’s quality of life and prognosis.
Physician, Nursing and CMCN credits valid to February 1, 2020

Integrating New and Emerging Therapies into the Treatment Paradigm in Hepatocellular Carcinoma (HCC): Expert Strategies for Improved Patient Outcomes

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. In 2017, it was expected that liver cancer accounted for approximately 788,000 deaths globally, making it the second leading cause of cancer-related deaths worldwide. The prevalence and mortality rate of liver cancer has been rising steadily over the past decade. Prognosis is especially poor for those with unresectable HCC. For the treatment of HCC, transplantation is an option for patients, however, there is a limited supply of good-quality deceased donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible in unresectable HCC.

Fortunately, clinicians have been equipped with new individualized options in the past year, including targeted therapies, which provide options for the unmet need of treatment in HCC, especially beyond first-line therapy. Tyrosine kinase inhibitors (TKIs) options have shown improved efficacy and safety in HCC, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.
Physician, Nursing and CMCN credits valid to February 1, 2020

Novel Treatment Advances and Approaches in the Management of Advanced Breast Cancer: Expert Strategies for Individualized Treatment

Regardless of race or ethnicity, Breast Cancer is the most common cancer found in women. Athough death rates have been steadily decreasing over the past 20 years, patients in the later stages of disease, when distant metastases are present, are less likely to survive. Therefore, therapy in the advanced, metastatic setting focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment is also increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents have been recently introduced or are in development for advanced breast cancer, including PARP inhibitors. With these options becoming available for the treatment of metastatic breast cancer, it is critical to provide medical professionals with updated clinical data and strategies.
Physician, Nursing and CMCN credits valid to February 1, 2020

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Expert Perspectives in Immunotherapy

Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 73,870 people in the United States in 2018 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the most deadly, with 9,940 people expected to die in 2018. Both of those numbers have been rising in recent years. In the early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor.
Physician, Nursing and CMCN credits valid to January 31, 2020

New Horizons in the Management of Sickle Cell Disease (SCD): What Managed Care Needs to Know About Novel Therapies

Sickle cell disease (SCD) is a hereditary blood disorder characterized by sickle-shaped red blood cells. It is a chronic, life-long, debilitating disease with many forms that can range in clinical severity from asymptomatic to life-threatening. In the US, SCD affects an estimated 90,000 to 100,000 Americans. Acute sickle cell pain crises, also referred to as vaso-occlusive crises, are a common painful complication of the disease and the main reason that patients seek medical care in hospitals. Currently, treatment options are limited. Several novel therapies are currently undergoing late stage clinical trials or regulatory review for SCD which will likely dramatically change the treatment paradigm. This webinar program on integrating emerging therapies into the treatment paradigm will address these novel treatment options, emerging value equations, the limitations of current treatment options, and recent clinical research on new agents to optimize the management of patients with SCD.
Physician, Nursing and CMCN credits valid to December 31, 2020

Evolving Considerations in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Closer Look at the Role of Immunotherapy

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the US, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with HPV has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in past years, the prognosis for metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This enduring webcast session will provide attendees with the latest information on immunotherapies, disease progression, adverse events and what managed care needs to know.
Physician, Nursing and CMCN credits valid to January 1, 2020

The Value of Personalized Treatment Sequencing for Castration-Resistant Prostate Cancer

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients’ disease progresses despite castrate levels of testosterone. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer and is used to monitor for disease recurrence. If the level of PSA is a high value, the more likely is the existence of this tumor. Since the approval of docetaxel, five additional therapeutic agents showing a survival benefit have been approved by the FDA in clinical trials. These include enzalutamide and abiraterone acetate, two agents designed specifically to affect the androgen axis; sipuleucel-T, which stimulates the immune system; cabazitaxel, a chemotherapeutic agent; alpharadin (or radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent; and the new generation antiandrogen agent enzalutamide. These agents have been tested in multiple disease stages of prostate cancer to determine whether or when patients might benefit from each treatment.
Physician, Nursing and CMCN credits valid to August 10, 2019

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.

Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.